-
Product Insights
NewDiastolic Heart Failure – Drugs In Development, 2024
Empower your strategies with our Diastolic Heart Failure (HFpEF) – Drugs In Development, 2024 report and make more profitable business decisions. Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart's main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the...
-
Product Insights
NewNon-infectious Uveitis – Drugs In Development, 2024
Empower your strategies with our Non-infectious Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. Noninfectious uveitis can result from an eye injury or a disease somewhere else in your body. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve...
-
Product Insights
NewFemale Hypoactive Sexual Desire Disorder – Drugs In Development, 2024
Empower your strategies with our Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses such as chronic renal failure, hyper-prolactinaemia, and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy. The Female Hypoactive Sexual Desire Disorder drugs in development market research report provide comprehensive information on...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments · Sustained Release Injectable...